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Abstract
We investigated whether the val158met functional polymorphism of catechol-o-methyltransferase influenced age-related changes in grey
matter density and volume, both in healthy individuals (n = 80, ages 18–79) and those with Parkinson’s disease (n = 50). Global grey matter
volumes and voxelwise estimates of grey matter volume and density were determined from structural magnetic resonance images at 3 T. Male
and female ValVal homozygotes (low prefrontal cortical dopamine) had more grey matter in early adulthood, but this difference disappeared
with increasing age. The insula and ventral prefrontal cortex had higher grey matter volume in younger, but not older, ValVal homozygotes.
Conversely, the dominant premotor cortex revealed genotypic differences in grey matter density in later life. There were no global or local
interactions between Parkinson’s disease and COMT val158met genotype on morphometry. Since the val158met polymorphism is associated
with differences in cortical dopamine metabolism, our data suggest a role for dopamine in cortical development followed by differential
vulnerability to cortical atrophy across the adult life span.
© 2008 Elsevier Inc. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/3.0/).
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1. Introduction
Dopamine is one of the most important regulators of brain
function. In adults it is closely associated with affective and
executive cognitive functions, especially of the frontal lobes
and basal ganglia, and it is central to the pathophysiology of
Parkinson’s disease and schizophrenia. Dopamine also influ-
ences cortical neuronal development (Krasnova et al., 2007;
Sherren and Pappas, 2005) and apoptosis (Iwatsubo et al.,
2007). This raises the possibility of structural as well as func-
tional consequences of chronic differences in dopaminergic
function.
∗ Corresponding author at: Medical Research Council Cognition and Brain
Sciences Unit, 15 Chaucer Road, Cambridge CB2 7EF, UK. Tel.: +44 1223
273 630; fax: +44 1223 359 062.
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Chronic differences in cortical dopamine arise in part
from functional polymorphisms in the gene for membrane
bound catechol-o-methyltransferase (COMT) the principal
catabolic enzyme for cortical dopamine (Yavich et al., 2007).
In contrast, COMT contributes little to striatal dopamine
catabolism (Tunbridge et al., 2004). The substitution of valine
(Val) by methionine (Met) at codon 158 causes a trimodal
distribution of enzymatic activity: ValVal vs. ValMet vs.
MetMet. Functionally, this is the most significant of the
many COMT polymorphisms. There is evidence of structural
effects of this val158met polymorphism in specific groups,
e.g. Val-hemizygote men with velo-cardio-facial syndrome
(van Amelsvoort et al., 2008) and adults with schizophre-
nia or a high risk of schizophrenia (McIntosh et al., 2007;
Ohnishi et al., 2006).
In Parkinson’s disease (PD) motor and cognitive
symptoms are also associated with chronic dopamine abnor-
malities within the cortex (Nagano-Saito et al., 2004; Rakshi
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et al., 1999) even though striatal pathology develops ahead of
cortical pathology (Braak et al., 2006). Even in early PD, the
val158met COMT polymorphism influences executive func-
tions that are mediated by frontal cortex (Williams-Gray
et al., 2008). The question arises therefore whether there
are common effects of the val158met polymorphism and
PD, e.g. do the cortical dopamine hypermetabolism in early
PD and the hyperdopaminergic state of MetMet homozy-
gotes have similar influences on cortical structure, or do they
interact?
The effects of PD and COMT must be interpreted in the
light of age related changes in grey matter morphometry
(Good et al., 2001). However, the effect of the val158met
polymorphism on age-related atrophy has not yet been iden-
tified across the adult lifespan. We therefore studied total
grey matter volume in adults with and without PD aged
18–79 years. We then analysed regional changes in grey mat-
ter volume and density. We hypothesised that the val158met
polymorphism interacts with global and regional rates of atro-
phy. We secondly hypothesised that such interactions would
be influenced by the chronic dopaminergic abnormalities
in PD.
2. Methods
2.1. Subjects
Eighty-two healthy adults participated, with no current
neurological or psychiatric history (bimodal age distribution:
old: 51–78, mean 66.2, S.D. 7.3, MMSE 29.2; and young:
20–47, mean 25.6, S.D. 6.7). Fifty patients with Parkinson’s
disease were recruited from the Cambridge PD Research
Clinic (UK Parkinson’s Disease Society Brain Bank clinical
diagnostic criteria), 50–80 years (mean 64.9, S.D. 9); with no
current depression (Beck Depression Inventory II score <13)
or dementia (clinical diagnostic criteria and recent MMSE
≥27). See supplementary Table S1 for patient subgroup char-
acteristics.
2.2. Genotype
DNA was extracted from peripheral blood samples using
standard phenol/chloroform methods (Williams-Gray et al.,
2007). The val158met genotype was determined by allelic dis-
crimination TaqMan assays. This generates an allele-specific
fluorescent reporter signal using the 5′ exonuclease activity of
Taq polymerase. This signal was measured after PCRs using
the HT7900 detection system (Applied Biosystems, Foster
City, CA).
2.3. MRI data
MRI used a high resolution MPRAGE sequence
(TR 2250 ms, TE 2.99 ms, FA 9 degrees, IT 900 ms,
256 × 256 × 192 isotropic 1 mm voxels) with a Siemens
Tim Trio 3 Tesla scanner. Pre-processing used SPM5
software (fil.ion.ucl.ac.uk/spm) and its VBM toolbox
(dbm.neuro.uni-jena.de/vbm) with Matlab 7 (Mathworks,
USA). Data underwent an iterative unified segmentation nor-
malisation procedure (Ashburner and Friston, 2005) into
three tissue segments (GM, WM, CSF) with bias correction
and warping to the Montreal Neurological Institute T1 tem-
plate. The Hidden Markov Random Fields model was applied
to constrain voxelwise segmentation based on nearest neigh-
bours (Cuadra et al., 2005). The normalised modulated and
unmodulated images of grey matter (GM) were smoothed by
an isotropic Gaussian kernel (FWHM 16 mm).
Global GM volume was analysed in SPSS 11.0 (Chicago,
Ill). We used a stepwise linear regression model including
age, sex, val158met genotype, disease (PD vs. control), the 2-
way interactions (‘age × genotype’, ‘age × sex’, ‘genotype ×
sex’, ‘disease group × age’, ‘disease group × genotype’) 3-
way interactions and a constant term.
Voxel based morphometry (Ashburner and Friston, 2000)
used general linear models to characterise the effects of
COMT (ValVal, ValMet or MetMet), age and PD on differ-
ences in regional grey matter density (unmodulated images)
and volume (modulated images). The models included
regressors that separately specified each COMT subgroup
(ValVal, ValMet, MetMet) for patients, older controls (>50)
and younger controls (<50)(see supplementary Fig. S1) and
total GM volume as a covariate. In addition, linear and
quadratic functions of the UPDRS were included for each
subgroup of patients.
Because of the predominant frontal distribution of cortical
dopamine and the evidence of COMT modulation of frontal
cortical functions, we restricted our study to a frontal lobe
region of interest (supplementary Fig. S2) including all the
frontal lobe regions and striatum as defined by Anatomical
Automatic Labelling in MNI space (Tzourio-Mazoyer et al.,
2002). We corrected for local smoothness and multiple com-
parisons (family wise error rate FWE p < 0.05). Additional
results of interest are presented at the secondary threshold
p < 0.001 unc.
3. Results
3.1. Global GM volume
Fig. 1 shows the adjusted GM volume changes with age
for the three genotypic groups of participants: ValVal, ValMet
and MetMet. Stepwise linear regression indicated three sig-
nificant variables: age (t(126) = −14.0, p < 0.001, rate = 0.4%
per year), sex (t(126) = −6.60, p < 0.001, 6.7% difference)
and the interaction between age and genotype (t(126) = 2.28,
p < 0.05, global atrophy rate difference between ValVal
and MetMet 0.16% per year) accounting for 67% of
GM volume variance (r = 0.823, F 3,126 = 88, p < 0.001).
Excluded factors had t-statistics in the range −0.6 < t < 0.6
(p > 0.5) except ‘disease × age’ (t = −1.3, p = 0.20). The
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Fig. 1. Global GM volume changes with age in ValVal (red), ValMet (green)
and MetMet (black) groups for healthy subjects and patients with Parkinson’s
disease (adjusted for gender differences). Lines indicate least squares linear
regression trends.
tolerances (>0.99) and variance inflation factors (<1.01) were
good.
A post hoc unpaired t-test of sex adjusted GM data from
young subjects (age < 50) confirmed that ValVal subjects
had more GM volume than MetMet subjects (t(17) = 2.32,
2-tailed p < 0.05). Because of collinearity between dis-
ease (PD) and age, a subsidiary analysis was run using
data from the older subjects only (age > 50, n = 100).
This supported a reduced model that included just age
and sex as significant factors. Age was highly significant
(t(98) = −3.74, p < 0.001, effect 0.36% per year) as was sex
(t(98) = −5.73,p < 0.001, 8.2% difference). The effects of
‘age × genotype’ (t(98) = −0.92) disease (t(98) = −0.05) and
genotype (t(98) = 0.2) were not significant.
3.2. Regionally speciﬁc changes in GM density
There were extensive differences between older and
younger healthy subjects collapsed across genotype (contrast
[zeros(1,9) −1 −1 −1 1 1 1]). Younger subjects had higher
density in medial and lateral prefrontal cortex, dorsally and
ventrally, and the caudate nuclei (supplementary Fig. S3A).
Across the whole group, there were no signifi-
cant regional differences between ValVal vs. MetMet
groups (SPM{t}contrast ± [1 0 0 0 0 0 −1 0 0 1 0 −1 1 0 −1]
or SPM{F} contrast [1 0 0 0 0 0 −1 0 0 1 0 −1 1 0 −1;
0 0 0 1 0 0 −1 0 0 0 1 −1 1 0 −1]). An interaction between
genotype and aging was identified in the left premotor
cortex (contrast [1 0 0 0 0 0 −1 0 0 1 0 −1 −2 0 2], peak
−14,−10,70, t = 3.56, p < 0.001, Fig. 2A). This interaction
was driven by differences between older ValVal and MetMet
subjects (>50 years) (contrast [1 0 0 0 0 0 −1 0 0 1 0 −1 0 0 0]
peak x,y,z = −12 −8 71, t = 4.42, FWE p < 0.05, Fig. 2C).
This suggests that with aging, subjects with MetMet
genotype had lost grey matter density from the dominant
hemisphere premotor region faster than was proportionate
to global atrophy (Fig. 2C). Frontal lobe GM density
did not differ between patients and older controls (con-
trast [1 0 0 1 0 0 1 0 0 −1 −1 −1 0 0 0]) and there were no
differences related to linear or quadratic functions of
disease severity (UPDRS) nor PD × genotype interactions
(±[1 0 0 0 0 0 −1 0 0 −1 0 1 0 0 0]).
3.3. Regionally speciﬁc changes in GM volume
There were extensive differences between old and
young healthy subjects, collapsing across the genotypes
([0 0 0 0 0 0 0 0 0 −1 −1 −1 1 1 1], supplementary Fig. S3C).
Fig. 2. SPM{t} maps of voxelwise morphometric interactions in healthy subjects between age and COMT genotype. (A) GM density differences increasing
with age (FWE p < 0.05) and (B) GM volume differences reducing with age (p < 0.001 unc.). Peaks of interest are indicated by the red arrows. (C) GM densities
in premotor cortex (MNI x,y,z = −12 −8 71) are plotted against age for ValVal (red), ValMet (green) and MetMet (black) groups. (D) GM volume in the left
frontal operculum/insula (MNI x,y,z = −33, 28, 1) are plotted against age for ValVal (red), ValMet (green) and MetMet (black) groups.
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Older subjects had regional loss of GM volume in the sup-
plementary motor area (1, −13, 73, t = 5.03, FWE p < 0.05),
pre-supplementary motor area (1, 20, 64, t = 5.01, FWE
p < 0.05) and medial prefrontal cortex (1, 42, 32, t = 7.45,
FWE p < 0.05), bilateral polar cortex (±30, 56, 26, t = 4.87,
FWE p < 0.05), ventrolateral prefrontal cortex (53,31,−13,
t = 5.62, FWE p < 0.05; −54, 19, 28, t = 5.11, FWE p < 0.05)
and caudate (−3, 6, 7, t = 6.63; 6,9,9,t = 5.22, FWE
p < 0.05).
There were weak regional effects of genotype amongst
healthy subjects ([0 0 0 0 0 0 0 0 0 1 0 −1 1 0 −1], see
supplementary Table S2) and interactions between geno-
type and age. Specifically, there were bilateral volume
differences (ValVal > MetMet) in the anterior insula and
ventral frontal cortex in young subjects (young subjects
<50 years: ValVal > MetMet difference in the left frontal
operculum/anterior insula, [0 0 0 0 0 0 0 0 0 0 0 0 1 0 −1],
peak −33, 28, 1, t = 4.97, FWE p < 0.05) with an interaction
between age and genotype ([0 0 0 0 0 0 0 0 0 −1 0 1 1 0 −1]
peak 32, 27,1, t = 4.18, p < 0.001 unc., see Fig. 2B). In
the older subpopulations (>50 years) there were volume
differences by genotype (ValVal > MetMet) in left premotor
cortex (−12, −8, 72, t = 4.06, p < 0.001 unc.).
PD was associated with GM volume loss in the medial
frontal cortex (peak −2, 36, 50, t = 4.34, FWE p < 0.05,
supplementary Fig. S3D) extending caudally (at p < 0.001
unc.) to pre-supplementary motor area (5,6,44, t = 3.95) with
additional peaks in precuneus (−3, −66, 46, t = 3.87) and
visual cortex (−2, −91, 1, t = 3.71). There were no signifi-
cant differences related to the linear or quadratic functions
of disease severity (UPDRS) nor PD × genotype interaction
(±[1 0 0 0 0 0 −1 0 0 −1 0 1 0 0 0]).
4. Discussion
Global GM volume was greater in young ValVal homozy-
gotes consistent with previous reports of Val vs. Met
hemizygotes, and despite previous negative reports for adult
homozygotes (Ohnishi et al., 2006; Zinkstok et al., 2006).
However, our data do not provide evidence of continuing
differences in ValVal homozygotes. Instead, the genotype
effect on global GM diminished with increasing age, sug-
gesting that the global developmental differences arising
from the COMT val158met polymorphism are lost during
adulthood.
These cortical structural differences may contribute to the
complex changes in executive function with normal aging.
Across the adult age span (35–85 years) ValVal homozygotes
have a faster decline in executive function over short inter-
vals (de Frias et al., 2005) but by old age (>65 years) the
val158met genotype has less influence (de Frias et al., 2005;
Starr et al., 2007). Our data suggest that the loss of this effect
of COMT genotype on executive function with age may be
due in part to the differential loss of GM although the mecha-
nism for this vulnerability to aging is currently unknown. It is
possible that the ValVal associated accelerated atrophy with
healthy aging is mechanistically associated with the ValVal
associated atrophy in schizophrenia (McIntosh et al., 2007;
Ohnishi et al., 2006) but further work is required to establish
such a link. However, in contrast to schizophrenia, idiopathic
PD did not interact with the effects of val158met COMT
genotype.
We also identified regional differences in the frontal
lobes, in terms of GM density and volume related to the
val158met genotype and interactions between age and geno-
type. These structural differences partially correlate with
regional differences in function. For example, fMRI stud-
ies have shown that the val158met polymorphism affects the
frontal activations during tasks of executive function in PD
(Williams-Gray et al., 2007) and health (Egan et al., 2001;
Meyer-Lindenberg et al., 2005). Typically there is greater
activation in lateral or medial prefrontal cortex at equiva-
lent levels of performance for healthy ValVal adults. Of these
regions, the ventral lateral prefrontal cortex is associated with
structural genotypic differences in grey matter in the current
study.
Parietal activity also differs between ValVal and MetMet
adults during some executive tasks (Williams-Gray et al.,
2007). However, the current structural data (supplementary
Table S2) and previous functional data of regional blood flow
(Meyer-Lindenberg et al., 2005) suggest that the parietal dif-
ference is secondary to the frontal effects of genotype, with
fronto-parietal connections, rather than a direct influence on
parietal cortical activity.
Clearly, there are limitations to the study. Our sample size
(n = 130) is generally sufficient for VBM but we have several
subgroups including medicated patients. Although our PD
population was larger than most previous VBM studies of
parkinsonian syndromes, and we reproduce VBM effects of
PD, we did not find an interaction between disease and COMT
genotype. This might be a false negative result, due to small
effect size. However, we cannot rule out two further possi-
bilities: a compensatory frontal cortical hyper-dopaminergic
state in early PD (Rakshi et al., 1999) or that dopaminergic
medication obviates structural changes arising from PD itself.
Therefore, independent replication of our findings would
be helpful, especially with unmedicated patients. Finally, it
should be noted that we have reported the complementary
information about human cortical change, including atrophy,
given by VBM of both modulated and unmodulated brain
images. However, VBM does not indicate whether these dif-
ferences arise from changes to the neuron soma, the neuropil
or even glia.
In summary, our data indicate age-related changes in
global and regional grey matter with the val158met polymor-
phism of COMT. These may be of functional significance in
executive and affective aspects of cognitive aging. We sug-
gest that functional effects of the val158met polymorphism
may be partly due to differences in the efficacy of current
dopamine synaptic transmission, but also differences in local
cortical structure.
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